Literature DB >> 15131310

GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization.

Robert J Harvey1, Ulrike B Depner, Heinz Wässle, Seifollah Ahmadi, Cornelia Heindl, Heiko Reinold, Trevor G Smart, Kirsten Harvey, Burkhard Schütz, Osama M Abo-Salem, Andreas Zimmer, Pierrick Poisbeau, Hans Welzl, David P Wolfer, Heinrich Betz, Hanns Ulrich Zeilhofer, Ulrike Müller.   

Abstract

Prostaglandin E2 (PGE2) is a crucial mediator of inflammatory pain sensitization. Here, we demonstrate that inhibition of a specific glycine receptor subtype (GlyR alpha3) by PGE2-induced receptor phosphorylation underlies central inflammatory pain sensitization. We show that GlyR alpha3 is distinctly expressed in superficial layers of the spinal cord dorsal horn. Mice deficient in GlyR alpha3 not only lack the inhibition of glycinergic neurotransmission by PGE2 seen in wild-type mice but also show a reduction in pain sensitization induced by spinal PGE2 injection or peripheral inflammation. Thus, GlyR alpha3 may provide a previously unrecognized molecular target in pain therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15131310     DOI: 10.1126/science.1094925

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  203 in total

1.  A crosstalk between β1 and β3 integrins controls glycine receptor and gephyrin trafficking at synapses.

Authors:  Cécile Charrier; Patricia Machado; Ry Y Tweedie-Cullen; Dorothea Rutishauser; Isabelle M Mansuy; Antoine Triller
Journal:  Nat Neurosci       Date:  2010-10-10       Impact factor: 24.884

2.  Molecular requirements for ethanol differential allosteric modulation of glycine receptors based on selective Gbetagamma modulation.

Authors:  Gonzalo E Yevenes; Gustavo Moraga-Cid; Ariel Avila; Leonardo Guzmán; Maximiliano Figueroa; Robert W Peoples; Luis G Aguayo
Journal:  J Biol Chem       Date:  2010-07-20       Impact factor: 5.157

Review 3.  Modulating inhibitory ligand-gated ion channels.

Authors:  Michael Cascio
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

4.  Cell-type-specific excitatory and inhibitory circuits involving primary afferents in the substantia gelatinosa of the rat spinal dorsal horn in vitro.

Authors:  Toshiharu Yasaka; Go Kato; Hidemasa Furue; Md Harunor Rashid; Motoki Sonohata; Akihiro Tamae; Yuzo Murata; Sadahiko Masuko; Megumu Yoshimura
Journal:  J Physiol       Date:  2007-03-08       Impact factor: 5.182

5.  Expression of glycine receptors and gephyrin in the rat cochlea.

Authors:  Julia Dlugaiczyk; Wibke Singer; Bernhard Schick; Heinrich Iro; Kristina Becker; Cord-Michael Becker; Ulrike Zimmermann; Karin Rohbock; Marlies Knipper
Journal:  Histochem Cell Biol       Date:  2008-01-30       Impact factor: 4.304

Review 6.  Analgesic targets: today and tomorrow.

Authors:  Ian W Rodger
Journal:  Inflammopharmacology       Date:  2009-06-09       Impact factor: 4.473

7.  A selective G betagamma-linked intracellular mechanism for modulation of a ligand-gated ion channel by ethanol.

Authors:  Gonzalo E Yevenes; Gustavo Moraga-Cid; Robert W Peoples; Günther Schmalzing; Luis G Aguayo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-12       Impact factor: 11.205

Review 8.  Molecular architecture of glycinergic synapses.

Authors:  Thomas Dresbach; Ralph Nawrotzki; Thomas Kremer; Stefanie Schumacher; Daniel Quinones; Martin Kluska; Jochen Kuhse; Joachim Kirsch
Journal:  Histochem Cell Biol       Date:  2008-08-22       Impact factor: 4.304

Review 9.  Chloride channels as drug targets.

Authors:  Alan S Verkman; Luis J V Galietta
Journal:  Nat Rev Drug Discov       Date:  2008-01-19       Impact factor: 84.694

10.  Presynaptic glycine receptors as a potential therapeutic target for hyperekplexia disease.

Authors:  Wei Xiong; Shao-Rui Chen; Liming He; Kejun Cheng; Yi-Lin Zhao; Hong Chen; De-Pei Li; Gregg E Homanics; John Peever; Kenner C Rice; Ling-gang Wu; Hui-Lin Pan; Li Zhang
Journal:  Nat Neurosci       Date:  2014-01-05       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.